GlassScriptPhysician profile
William Caleb Wilson
NPI 1295223873
$3,946.79
in general payments reported to CMS, 2019-2025
20 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $554 · 2023: $917 · 2024: $757 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.82 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $692.54 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $500.28 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $390.68 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $338.88 | 2022-2025 | Invega Sustenna, Spravato |
| Corium, LLC | $334.13 | 2022-2025 | Azstarys |
| Alkermes, INC. | $283.88 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $231.80 | 2022-2025 | Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $226.07 | 2024-2025 | Qelbree |
| Abbvie INC. | $224.59 | 2022-2024 | Vraylar |
| Neurocrine Biosciences, INC. | $173.42 | 2022-2025 | |
| Axsome Therapeutics, INC. | $158.48 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $142.37 | 2022-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $83.38 | 2025 | Cobenfy |
| Bausch Health US, LLC | $61.50 | 2022-2024 | Wellbutrin, Aplenzin |
| Collegium Pharmaceutical, INC. | $22.02 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.94 | 2022 | |
| Boston Scientific Corporation | $17.67 | 2025 | Watchman Access System |
| Tris Pharma INC | $16.81 | 2025 | Dyanavel Xr |
| Indivior INC. | $14.22 | 2023 | Perseris |
| Neos Therapeutics, LP | $14.13 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.